Notice of Correction for Announcement of Requirements and Registration for “Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test” Challenge, 68020-68021 [2016-23854]
Download as PDF
<![CDATA[
sradovich on DSK3GMQ082PROD with NOTICES
68020
Federal Register / Vol. 81, No. 191 / Monday, October 3, 2016 / Notices
7W264, Rockville, MD 20892–9750,
240–276–6384, gravesr@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Provocative Questions—PQ4.
Date: November 3, 2016.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute,
Shady Grove, 9609 Medical Center
Drive, Room 7W032/034, Rockville, MD
20850, (Telephone Conference Call).
Contact Person: Zhiqiang Zou, MD,
Ph.D., Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute,
9609 Medical Center Drive, Room
7W242, Rockville, MD 20892–9750,
240–276–6372, zouzhiq@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Fundamental Mechanisms of Affective
and Decisional Process in Cancer
Control.
Date: November 4, 2016.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute,
Shady Grove, 9609 Medical Center
Drive, Room 2W910, Rockville, MD
20850, (Telephone Conference Call).
Contact Person: Thomas A. Winters,
Ph.D., Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute,
9609 Medical Center Drive, Room
7W112, Rockville, MD 20892–9750,
240–276–6386, twinters@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Provocative Questions—PQ6.
Date: November 4, 2016.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute,
Shady Grove, 9609 Medical Center
Drive, Room 6W034, Rockville, MD
20850, (Telephone Conference Call).
Contact Person: Zhiqiang Zou, MD,
Ph.D., Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute,
9609 Medical Center Drive, Room
7W242, Rockville, MD 20892–9750,
240–276–6372, zouzhiq@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Provocative Questions—PQ8.
Date: November 10, 2016.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute,
Shady Grove, 9609 Medical Center
Drive, Room 7W032/034, Rockville, MD
20850, (Telephone Conference Call).
VerDate Sep<11>2014
17:56 Sep 30, 2016
Jkt 241001
Contact Person: Yisong Wang, Ph.D.,
Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute,
9609 Medical Center Drive, Room
7W240, Rockville, MD 20892–9750,
240–276–7157, yisong.wang@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Provocative Questions in Cancer with
an Underlying HIV Infection.
Date: November 16, 2016.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute,
Shady Grove, 9609 Medical Center
Drive, Room 4E030, Rockville, MD
20850, (Telephone Conference Call).
Contact Person: Clifford W.
Schweinfest, Ph.D., Scientific Review
Officer, Special Review Branch,
Division of Extramural Activities,
National Cancer Institute, 9609 Medical
Center Drive, Room 7W108, Rockville,
MD 20892–9750, 240–276–6343,
schweinfestcw@mail.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Multi–Omics
in Osteoporosis.
Date: October 25, 2016.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 2W200, 7201 Wisconsin
Avenue, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Nijaguna Prasad, MS,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute of Aging,
National Institutes of Health, Bethesda, MD
20892, 301–496–9667, nijaguna.prasad@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: September 27, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–23734 Filed 9–30–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
Dated: September 27, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–23735 Filed 9–30–16; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
Notice of Correction for
Announcement of Requirements and
Registration for ‘‘Antimicrobial
Resistance Rapid, Point-of-Need
Diagnostic Test’’ Challenge
The National Institutes of Health
(NIH) is correcting a notice previously
published in the Federal Register on
September 8, 2016 (81 FR 62150), titled
‘‘Announcement of Requirements and
Registration for ‘Antimicrobial
Resistance Rapid, Point-of-Need
Diagnostic Test’ Challenge.’’ The notice
announced the Antimicrobial Resistance
Rapid, Point-of-Need challenge
competition that may result in the
awarding of $20 million dollars for the
successful development of new,
innovative, accurate, and cost-effective
in vitro diagnostic tests that would
rapidly inform clinical treatment
decisions and be of significant clinical
and public health utility to combat the
development and spread of antibiotic
resistant bacteria and improve antibiotic
stewardship.
The NIH is correcting and clarifying
several components of the Challenge
competition including:
(1) The letter of intent must be
submitted by December 23, 2016, for all
‘‘Solvers’’ planning to submit for the
Step 1 (Theoretical) stage of the
competition. The September 8, 2016
announcement incorrectly stated that
the letter of intent prior to Step 1 was
E:\FR\FM\03OCN1.SGM
03OCN1
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 81, No. 191 / Monday, October 3, 2016 / Notices
required but a specific due date was not
stated.
(2) Any Appendix submitted for Step
1 of the Challenge competition must be
limited to 5 pages or less in length. If
a longer Appendix is submitted, only
the first 5 pages will be considered by
the Technical Evaluation Panel and the
Judging Panel. The September 8, 2016,
announcement incorrectly stated that
there was no page length for the
Appendix material.
(3) Submissions for Step 1 of the
Challenge competition received after the
deadline of January 9, 2017, at 11:59
p.m. ET will be disqualified and not
evaluated by the Technical Evaluation
Panel or Judging Panel.
(4) Solvers may submit corrections or
additional materials in support of their
Step 1 submissions so long as the NIH
receives the materials by the deadline of
January 9, 2017, at 11:59 p.m. ET.
Corrections or additional materials for
Step 1 will not be accepted or evaluated
by the Technical Evaluation Panel or
Judging Panel if they are received after
January 9, 2017 at 11:59 p.m. ET.
(5) The NIH will perform an initial
review of all submissions to ensure they
are complete and within the scope of
the Challenge competition. Submissions
that are incomplete will be
administratively disqualified and will
not be evaluated by the Technical
Evaluation Panel or the Judging Panel.
(6) The NIH and Assistant Secretary
for Preparedness and Response/
Biomedical Advanced Research and
Development Authority may determine
that based on the number of
submissions received for Step 1 that less
competitive submissions will not be
discussed by the Technical Evaluation
Panel during the Panel’s meeting.
(7) The ‘‘Solver’’ needs to address the
NIH Human Subjects Protections and
Inclusion of Women, Children, and
Minorities policies in their submissions
for Step 1 of this competition.
(8) Members of the Technical
Evaluation Panel are not eligible to
participate in or contribute to any
proposal for Step 2 and Step 3 of the
Challenge competition.
(9) Any Solver is eligible for Step 2 of
this Challenge competition. For
example, if a Step 1 ‘‘Solver’’ is not
identified as a semifinalist, he/she may
still submit for Step 2 of this
competition and those who did not
submit a Step 1 proposal may still
submit a proposal for Step 2.
(10) All submissions for Step 1, 2, and
3 must be in English.
For further information about the
Antimicrobial Resistance Diagnostic
Challenge competition, please contact
Robert W. Eisinger, Ph.D., NIH, 301–
VerDate Sep<11>2014
17:56 Sep 30, 2016
Jkt 241001
68021
496–2229 or by email
Robert.eisinger@nih.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: September 27, 2016.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
Substance Abuse and Mental Health
Services Administration
[FR Doc. 2016–23854 Filed 9–30–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning Grant (R34) and NIAID Investigator
Initiated Program Project Applications (P01).
Date: October 28, 2016.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892,
(Telephone Conference Call).
Contact Person: Zhuqing (Charlie) Li,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, Room # 3G41B, National Institutes
of Health/NIAID, 5601 Fishers Lane,
MSC9823 Bethesda, MD 20892–9823, (240)
669–5068, zhuqing.li@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 27, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–23736 Filed 9–30–16; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
Internet at https://www.samhsa.gov/
workplace.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, 5600
Fishers Lane, Room 16N03A, Rockville,
Maryland 20857; 240–276–2600 (voice).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
E:\FR\FM\03OCN1.SGM
03OCN1
]]>Agencies
[Federal Register Volume 81, Number 191 (Monday, October 3, 2016)]
[Notices]
[Pages 68020-68021]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23854]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Correction for Announcement of Requirements and
Registration for ``Antimicrobial Resistance Rapid, Point-of-Need
Diagnostic Test'' Challenge
The National Institutes of Health (NIH) is correcting a notice
previously published in the Federal Register on September 8, 2016 (81
FR 62150), titled ``Announcement of Requirements and Registration for
`Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test'
Challenge.'' The notice announced the Antimicrobial Resistance Rapid,
Point-of-Need challenge competition that may result in the awarding of
$20 million dollars for the successful development of new, innovative,
accurate, and cost-effective in vitro diagnostic tests that would
rapidly inform clinical treatment decisions and be of significant
clinical and public health utility to combat the development and spread
of antibiotic resistant bacteria and improve antibiotic stewardship.
The NIH is correcting and clarifying several components of the
Challenge competition including:
(1) The letter of intent must be submitted by December 23, 2016,
for all ``Solvers'' planning to submit for the Step 1 (Theoretical)
stage of the competition. The September 8, 2016 announcement
incorrectly stated that the letter of intent prior to Step 1 was
[[Page 68021]]
required but a specific due date was not stated.
(2) Any Appendix submitted for Step 1 of the Challenge competition
must be limited to 5 pages or less in length. If a longer Appendix is
submitted, only the first 5 pages will be considered by the Technical
Evaluation Panel and the Judging Panel. The September 8, 2016,
announcement incorrectly stated that there was no page length for the
Appendix material.
(3) Submissions for Step 1 of the Challenge competition received
after the deadline of January 9, 2017, at 11:59 p.m. ET will be
disqualified and not evaluated by the Technical Evaluation Panel or
Judging Panel.
(4) Solvers may submit corrections or additional materials in
support of their Step 1 submissions so long as the NIH receives the
materials by the deadline of January 9, 2017, at 11:59 p.m. ET.
Corrections or additional materials for Step 1 will not be accepted or
evaluated by the Technical Evaluation Panel or Judging Panel if they
are received after January 9, 2017 at 11:59 p.m. ET.
(5) The NIH will perform an initial review of all submissions to
ensure they are complete and within the scope of the Challenge
competition. Submissions that are incomplete will be administratively
disqualified and will not be evaluated by the Technical Evaluation
Panel or the Judging Panel.
(6) The NIH and Assistant Secretary for Preparedness and Response/
Biomedical Advanced Research and Development Authority may determine
that based on the number of submissions received for Step 1 that less
competitive submissions will not be discussed by the Technical
Evaluation Panel during the Panel's meeting.
(7) The ``Solver'' needs to address the NIH Human Subjects
Protections and Inclusion of Women, Children, and Minorities policies
in their submissions for Step 1 of this competition.
(8) Members of the Technical Evaluation Panel are not eligible to
participate in or contribute to any proposal for Step 2 and Step 3 of
the Challenge competition.
(9) Any Solver is eligible for Step 2 of this Challenge
competition. For example, if a Step 1 ``Solver'' is not identified as a
semifinalist, he/she may still submit for Step 2 of this competition
and those who did not submit a Step 1 proposal may still submit a
proposal for Step 2.
(10) All submissions for Step 1, 2, and 3 must be in English.
For further information about the Antimicrobial Resistance
Diagnostic Challenge competition, please contact Robert W. Eisinger,
Ph.D., NIH, 301-496-2229 or by email Robert.eisinger@nih.gov.
Dated: September 27, 2016.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
[FR Doc. 2016-23854 Filed 9-30-16; 8:45 am]
BILLING CODE 4140-01-P
